<DOC>
	<DOCNO>NCT01437384</DOCNO>
	<brief_summary>36 healthy adult men woman enrol goal 24 subject complete entire study . The study consist pre-treatment phase treatment phase . The pre-treatment phase include screen baseline period 1 . The treatment phase consist 4 treatment period : Treatment Period 1 - administration first E5501 oral dose ; Treatment Period 2 - administration verapamil second E5501 oral dose ; Treatment Period 3 - administration third E5501 dose ; Treatment Period 4 - concomitant administration cyclosporine fourth E5501 dose . A baseline period precede treatment period . The screening period 13 day duration . After fulfil screening requirement , subject check clinic Day -1 baseline assessment . They domicile clinical test facility 6 day Treatment Periods 1 , 3 , 4 return intermittently study procedure 8 outpatient visit . They domicile clinical test facility least 14 day Treatment Period 2 return intermittently study procedure 7 outpatient visit .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Study Healthy Subjects Comparing Interactions Between E5501 Verapamil Cyclosporine .</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion : Healthy adult men woman ( age 18 55 year ) Body mass index great equal 18kg/m2 less equal 32kg/m2 time Screening Baseline Platelet count 120x109/L 300x109/L Baseline Women childbearing potential must agree use highly effective method contraception , estrogenbased hormonal contraceptive , treatment phase study Exclusion : Evidence clinically significant cardiovascular , hepatic , gastrointestinal , renal , respiratory , endocrine , hematologic , neurologic , psychiatric disease abnormality know history gastrointestinal surgery could impact PK study Agents associate thrombotic event ( include oral contraceptive ) must discontinue within 30 day first study drug administration Evidence organ dysfunction clinically significant event illness subject 's medical history , e.g. , history splenectomy History arterial venous thrombosis , include partial complete thromboses ( e.g. , stroke , transient ischemic attack , myocardial infarction , deep vein thrombosis , pulmonary embolism ) . Known family history hereditary thrombophilic disorder ( e.g. , Factor V Leiden , antithrombin III deficiency , etc . ) Hemoglobin less low limit normal level ( woman , 7.1 mmol/L ; men , 8.1 mmol/L ) In addition , standard criterion healthy volunteer use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>